High expression of ONECUT2 and PRSS21 have been reported to be associated with poorer prognosis in various cancers including prostate cancer, hepatocellular carcinoma, and gastric cancer (Liu et al., 2021; Pollan et al., 2021; Shen et al., 2021; Sun et al., 2021). Here, ONECUT2 is linked to prostate cancer.